Alteplase
Based on 1 Customer Validation
Alteplase (Actilyse; Activase), a tissue plasminogen activator prepared by recombination, is a thrombolytic agent that play important roles in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters.
The product size below only indicate the effective content of Alteplase. The ratio of Alteplase effective content : total content = 1:46-1:50. The actual ratio depends on the batch.)
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 105857-23-6
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
The product size below only indicate the effective content of Alteplase. The ratio of Alteplase effective content : total content = 1:46-1:50. The actual ratio depends on the batch.)
Alteplase ( 8.3 and 250 μg/mL, 12 h) shows a signifcant reduction in viability of human fetal retinal pigment epithelial (hfRPE cells)[4].
Alteplase (8.3 and 250 μg/mL, 0-6 h) signifcantly decreases the transepithelial resistance in a time-dependent manner and induces cell death in hfRPE cells[4].
Product Information
This product contains L-arginine, phosphoric acid, polysorbate 80, etc. as auxiliary materials.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:hfRPE cells
-
Concentration:8.3 and 250 μg/mL
-
Incubation Time:12 h
-
Result:Decreased the number of cells that adhered to the cell culture dish, i.e., the number of living cells following treatment of hfRPE cells with 83 μg/ml alteplase for 12 h and 250 μg/ml alteplase for 6 and 12 h.
-
Cell Line:hfRPE cells
-
Concentration:8.3 and 250 μg/mL
-
Incubation Time:0-6 h
-
Result:Increased The number of positive hfRPE cells for both EthD-III and FITC-Annexin V staining.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice model of thromboembolic stroke[3]
-
Dosage:0.9-10 mg/kg
-
Administration:i.v., 20 to 40 minutes post ictus or 180 and 240 minutes post ictus
-
Result:Significantly reduced the final infarct volume in the early stage.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
6.24×105 IU/mg protein
Chemical Information
-
CAS No. 105857-23-6
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Alteplase]
-
Synonyms
Actilyse; Activase
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
용액&용해도
H2O : ≥ 12.5 mg/mL
* "≥" means soluble, but saturation unknown.
순도&문서
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. J Bastecký, et al. [Actilyse (a recombinant tissue-type plasminogen activator] in the treatment of acute myocardial infarct. Comparison of the effects of Actilyse and streptokinase]. Vnitr Lek. 1994 May;40(5):293-8. [Content Brief]
[2]. Micieli G, et al. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009;5(1):397-409. [Content Brief]
[3]. Orset C, et al. Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis. Stroke. 2016 May;47(5):1312-1318. [Content Brief]
[4]. Kimura S, et al. Cytotoxic effects of alteplase, a recombinant tissue plasminogen activator, on human retinal pigment epithelial cells. Jpn J Ophthalmol. 2021 Sep;65(5):731-739. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)